Operational Costs Compared: SG&A Analysis of Viatris Inc. and Bausch Health Companies Inc.

A Decade of SG&A: Viatris Inc. vs. Bausch Health Companies Inc.

In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. Over the past decade, Viatris Inc. and Bausch Health Companies Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Viatris Inc. saw a significant increase of approximately 210% in SG&A expenses, peaking in 2023. In contrast, Bausch Health Companies Inc. experienced a more modest growth of around 44% over the same period.

Key Insights

• Viatris Inc.: The company's SG&A expenses surged, particularly from 2020 onwards, reflecting strategic investments and potential restructuring efforts.
• Bausch Health Companies Inc.: Despite fluctuations, the company maintained a relatively stable SG&A trajectory, indicating consistent operational strategies.

These trends highlight the diverse approaches these companies take in managing operational costs, offering valuable insights for investors and industry analysts alike.